• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet reports 21% sales growth in Q1, raises 2023 guidance

May 5, 2023 By Sean Whooley

Insulet logo

Insulet [WtwhTicker symbol=”PODD”](Nasdaq:PODD)[/WtwhTicker] shares are up on first-quarter results that topped the consensus forecast.

Shares of PODD rose more than 3% to 331.60 apiece by midday trading today. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly.

The Acton, Massachusetts–based automated insulin delivery technology developer posted profits of $23.8 million, according to the company’s earnings report yesterday evening. That amounts to 34¢ per share on sales of $358.1 million for the three months ended March 31, 2023.

Insulet recorded a 14.4% bottom-line slide on sales growth of 21.2%. Total Omnipod revenue came in at $357.6 million for an increase of 32.7% year over year. Insulet rolled out its next-generation Omnipod 5 in August 2022, following the system’s FDA clearance in February 2022. The company also earned FDA clearance for the Omnipod GO, a basal-only insulin delivery device, last month.

Adjusted to exclude one-time items, earnings per share totaled 23¢. That landed 12¢ ahead of Wall Street projections. Sales also topped expectations as analysts looked for sales of $330.8 million.

“Our first quarter results demonstrate strong financial performance, including unprecedented results for U.S. Omnipod, and ongoing strategic progress,” said Jim Hollingshead, Insulet president and CEO. “Omnipod 5 is quickly transforming diabetes management in the U.S. by offering improved outcomes and quality of life and we remain on track to begin our staged international roll-out in a matter of months. We expect 2023 to be another successful year as we build on our momentum and further execute our mission to improve the lives of people with diabetes.”

Insulet increased its revenue guidance for the full 2023 fiscal year. After previously projecting growth between 14% and 19%, the company now expects a revenue increase of 18% to 22%. Insulet expects Omnipod growth to come in at 21% to 25%, previously suggesting 17% to 22%.

The analysts’ view

BTIG analysts Marie Thibault and Sam Eiber wrote that they expect demand for Omnipod 5 to “continue in the near-to-medium term.” They cited catalysts like iOS integration, expansion to type 2 diabetes, integration with next-gen CGMs and international launches.

“We anticipated a strong Q1 result but note expectations were lofty into the print given PODD’s premium multiple,” they wrote. “PODD remains one of the highest-quality names in our universe.”

The analysts reiterated their “Buy” rating for Insulet.

This story originally ran on May 4, 2023. Updated May 5 with the next-day stock price.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS